LGND Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals, Inc. has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of -82.06%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $243.44, signalling upside risk potential of 26.16%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $90.63 which suggests that it could grow by 18.73%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.007, which suggesting that the stock is 0.719% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.278, suggesting its less volatile than the S&P 500 by 72.158%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 92.88x while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 15.12x versus 13.00x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of 21.47%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Johnson & Johnson's return on equity of 33.27%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $243.44, signalling upside risk potential of 26.16%. On the other hand Johnson & Johnson has an analysts' consensus of $212.00 which suggests that it could fall by -3.05%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.

Ligand Pharmaceuticals, Inc. has a beta of 1.007, which suggesting that the stock is 0.719% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.861%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.35% to investors and pays a quarterly dividend of $1.30 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is lower than Johnson & Johnson's net income of $5.2B. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 92.88x while Johnson & Johnson's PE ratio is 21.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 15.12x versus 5.75x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of 81.15%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Krystal Biotech, Inc.'s return on equity of 19.91%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $243.44, signalling upside risk potential of 26.16%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $273.60 which suggests that it could fall by -4.01%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Krystal Biotech, Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.007, which suggesting that the stock is 0.719% more volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.705%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are larger than Krystal Biotech, Inc. quarterly revenues of $97.8M. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is higher than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 92.88x while Krystal Biotech, Inc.'s PE ratio is 42.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 15.12x versus 22.79x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of 33.68%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Merck & Co., Inc.'s return on equity of 39.63%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $243.44, signalling upside risk potential of 26.16%. On the other hand Merck & Co., Inc. has an analysts' consensus of $113.33 which suggests that it could grow by 4.27%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Merck & Co., Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.007, which suggesting that the stock is 0.719% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.01% to investors and pays a quarterly dividend of $0.85 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 92.88x while Merck & Co., Inc.'s PE ratio is 14.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 15.12x versus 4.29x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.